Jazz Pharmaceuticals plc (JAZZ)
Investing in Jazz (JAZZ)? Don't Miss Assessing Its International Revenue Trends
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.
Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
Jazz Pharmaceuticals plc. (NASDAQ:JAZZ ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Rob Iannone - Executive Vice President and Global Head-R&D Phil Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Marc Goodman - Leerink Jessica Fye - JPMorgan Annabel Samimy - Stifel.
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.30 per share, beating the Zacks Consensus Estimate of $4.68 per share. This compares to earnings of $4.51 per share a year ago.
3 Biotech Stocks to Buy on the Dip: July 2024
The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian paradigm, the ecosystem is safe.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
Investors need to pay close attention to JAZZ Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is performing well despite generic Xyrem and Lumryz competition, and Jazz is seeing healthy patient and net sales growth of Xywav. Jazz expects to deliver 4% to 9% revenue growth in 2024.
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Thursday, Jazz Pharmaceuticals plc JAZZ released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study.
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
